Citizens reiterates Nuvation Bio at Market Outperform with $10 PT

Citizens: Citizens JMP is an investment banking and equity research firm that provides analysis and ratings on public companies, with particular attention to the biotechnology and healthcare sectors. In relation to this news, the firm has reiterated its Market Outperform rating on Nuvation Bio, emphasizing IBTROZI’s best-in-class attributes and early commercial momentum as drivers for continued upside. Its research notes often incorporate recent clinical updates and launch metrics to inform investment recommendations. Nuvation Bio: Nuvation Bio is a biopharmaceutical company developing novel oncology therapeutics, with a focus on targeted treatments for specific genetic alterations in cancer. Its lead asset IBTROZI (taletrectinib) is a next-generation ROS1 inhibitor approved by the FDA for locally advanced or metastatic ROS1-positive non-small cell lung cancer. The company’s commercial execution on the IBTROZI launch forms the basis for ongoing positive analyst coverage, including reiterations of favorable ratings tied to the drug’s competitive profile. Analyst Coverage: Equity research firms have maintained positive ratings on Nuvation Bio in recent months, citing ongoing progress with the IBTROZI commercial launch. Product Positioning: IBTROZI is positioned as a next-generation ROS1 tyrosine kinase inhibitor with demonstrated activity across lines of therapy in ROS1-positive non-small cell lung cancer. Recent Data Support: Updated subgroup analyses from pivotal TRUST studies on IBTROZI were presented at a major 2026 lung cancer conference, reinforcing consistent efficacy regardless of prior treatment or fusion partner.